# UPDATE ON PROGRESS OF MPP SUBLICENSEES

Till December 2025

medicinespatentpool.org

# SUMMARY

- This presentation showcases the progress made by MPP licensees (generic pharmaceutical companies)
- To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, 1 HIV technology platform, 3 hepatitis C direct-acting antivirals, 1 tuberculosis treatment, 4 long-acting technologies, 1 cancer treatment, 3 oral antiviral treatments for COVID-19, 1 post partum haemorrhage medicine and 16 Covid-19 technologies.
- Licensed products are developed by multiple MPP licensees, with an aim of encouraging competition, reducing market prices and providing faster access to medicines for people living in low- and middle-income countries (LMICs)
- Generic medicines are developed and filed with stringent regulatory authorities such as the U.S. Food and Drug Administration (USFDA) and the World Health Organization prequalification (WHO-PQ), ensuring availability of quality assured products in LMICs.
- This presentation gives a snapshot of the development of each licensed product and when the product may be filed with regulators. It also shows which countries the local filing is taking place in and when – thereby providing a clearer picture of availability of new formulations in each country.

# PARTNERSHIPS WITH INNOVATORS ACROSS DIFFERENT DISEASE AREAS

## TUBERCULOSIS

- Johns Hopkins University
- Pfizer

sutezolid

## HIV

- abbvie — lopinavir Ritonavir (adult & paediatric)
- Janssen — darunavir (paediatric; (non-assert)
- MSD — raltegravir (paediatric)
- ViiV Healthcare — abacavir (paediatrics)
- Gilead — bictegravir; cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide; tenofovir disoproxil fumarate
- Bristol Myers Squibb — atazanavir
- Boehringer Ingelheim — nevirapine (non-assert)
- NIH — darunavir related
- ViiV Healthcare — cabotegravir long-acting (for HIV PrEP and Treatment); Dolutegravir (adult & paediatric)

## CANCER

- Novartis — nilotinib

## MATERNAL HEALTH

- Ferring Pharmaceuticals — heat-stable carbetocin

## HEPATITIS C

- Bristol Myers Squibb — daclatasvir
- Pharco Pharmaceuticals — ravidasvir
- abbvie — glecaprevir/pibrentasvir

## COVID-19

- CSIC — Elisa antibody Tech MVA-S(3P) (vaccine candidate)
- MSD — molnupiravir
- Pfizer — nirmatrelvir
- MVC Medigen Vaccine Biologics Corp — vaccine MVC-COV1901
- Universidad de Chile — NAb detection tech for SARS-COV-2
- NIH — Early-stage vaccine & diagnostic tools*
- Shionogi — ensitrelvir fumaric acid
- SD Biosensor — rapid diagnostic testing tech

## LONG-ACTING TECHNOLOGIES

- University of Liverpool — solid drug nanoparticles technology (disease agnostic)
- MedinCell — mdc-STM (malaria LAI)
- Tandem Nano Ltd — LA tech for HCV, TB & malaria
- University of Washington — TLD LAI (HIV)

- For 11 innovative therapeutics, early-stage vaccines & diagnostic tools for COVID-19

# MPP PARTNERSHIPS WITH GENERICS AND PRODUCT DEVELOPERS

**abacavir (paed)**
Aurobindo

**atazanavir $**
Aurobindo
Cipla
Desano
Emcure
Viatris

**cabotegravir (for PreP & treatment)**
Aurobindo
Cipla
Viatris

**bictegravir**
Adcock Ingram
Aurobindo
Desano
Emcure
Laurus Labs
Lupin
Macleods

**cobicistat**
Adcock Ingram
Emcure
Lupin

**dolutegravir**
Adcock Ingram#
Cipla#
Desano#
Emcure#
Hetero^
Laurus Labs#
Lupin#
Macleods#
Mangalam
Micro Labs#
Strides#
Sun Pharma^
Viatris^

**emtricitabine $**
Adcock Ingram
Arene
Emcure
Lupin

**elvitegravir**
Adcock Ingram

**Lopinavir, ritonavir $**
Adcock Ingram
Arene
Aurobindo
Cipla*
Desano
Emcure
Hetero**
Lupin
Sun Pharma

**raltegravir / Paed**
Lupin

**tenofovir alafenamide**
Adcock Ingram
Aurobindo
Desano
Emcure
Laurus Labs
Lupin
Macleods
Micro Labs
Natco

**tenofovir disoproxil fumarate $**
Adcock Ingram
Arene

**sutezolid / John Hopkins University**
TB Alliance!

**sutezolid / Pfizer**
Gates Medical Research Insititute!

## Hepatitis C

**daclatasavir**
Beximco
Cipla
Hetero
Laurus Labs
Natco
Zydus
Viatris

**glecaprevir/pibrentasvir**
Remington
USV
Viatris

## HIV

**rapid diagnostic testing technology**
Codix Bio!

**elisa antibody technology**
Biotech Africa!

## COVID-19 & Technology

**nirmatrelvir**
Apeloa
Arene
Celltrion
Cipla
Desano
Dongbang
Fosun Pharma
Hetero
Huahai
Jiuzhou
Neolpharma
Viatris

**molnupiravir**
Desano
Fosun
Kimia Farma
MSNc
Jiuzhou
Neolpharma
Viatris

**ensitrelvir**
Charioteer
Stellapharm

## Tuberculosis

## Cancer

**nilotinib**
Dr. Reddy's
Eugia
Hetero
PT Anvita Pharma

* Only LPV/r paed licence **Also have LPV/r paed licence #Also have DTG paed licence ^Also have DTG paed & UMICs licence !product developer $products where patents are no longer valid

**Argentina**
Sinergium Biotech

**Bangladesh**
Beximco
Incepta Vaccine Ltd

**Brazil**
Bio-Manguinhos/Fiocruz
Nordec

**China**
Apeloa
Aurisco
Biochem
Carelife
Charioteer
Desano China
Fosun
HEC Group
Huahai
Jiuzhou
Langhua
Lepu
Lonzeal
Yao Pharma

**Dominican Republic**
Laboratorios Magnachem

**Egypt**
BioGeneric Pharma S.A.E

**France**
Tridem Pharma

**India**
Amneal
Arene
Aurobindo
BDR
Biocon
Biological E
Biophore
Cadila
Cipla
Desano India
Divi's
DRL
Emcure
Eugia
Glenmark Lifesciences
Glenmark Pharma
Granules
Hetero
Honor Labs
Laurus
Lupin
Macleods
Mangalam
Microlabs
MSN
Natco
Optimus
Shilpa Medicare Ltd
SMS Pharma
Strides
Sun
Syngene
Torrent
USV
Viatris (Mylan)
VKT Pharma Pvt Ltd
Zenara Pharma Pvt Ltd
Zydus

**Indonesia**
Biofarma
BrightGene (PT Anvita Pharma)
Kimia Farma

**Israël**
Teva

**Jordan**
Hikma

**Kenya**
BioVax
UCL

**Mexico**
Neolpharma

**Nigeria**
Biovaccines Nigeria Limited

**Pakistan**
National Institute of Health
Remington

**Senegal**
Institut Pasteur de Dakar

**Serbia**
Institut Torlak
FHI Zdravlje

**South Africa**
Adcock Ingram
Aspen
Biovac
CPT

**South Korea**
Afrigen
Celltrion Inc
Celltrion Pharm
Dongbang Futuretech
Hanmi

**Switzerland**
Sandoz

**Tunisia**
Institut Pasteur de Tunis

**Ukraine**
Darnytsia
Lekhim

**Vietnam**
Polyvac
Stellapharm

**Product developers**
Biotech
Codix Bio
TB Alliance
Gates MRI

mpp

# MPP's network of generic manufacturers, product developers and mRNA programme partners, are in 24 countries


Since 2010

93 generic manufacturers, product developers and mRNA programme partners

# TRIANGLE CHARTS

**Triangle charts** represent a comparative analysis of each MPP licensee's filings with WHO-PQ and/or USFDA for each product

# TRIANGLE CHARTS: A SNAPSHOT




**Companies approved** Companies filed Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

See following slides for explanation

# TRIANGLE CHARTS EXPLAINED: 1/7



# TRIANGLE CHARTS EXPLAINED: 2/7



# TRIANGLE CHARTS EXPLAINED: 3/7




No. of companies that have **received approval out of total companies filed** with WHO-PQ/USFDA

# TRIANGLE CHARTS EXPLAINED: 4/7




Total no. of **companies** that **have been approved by** WHO-PQ/USFDA

# TRIANGLE CHARTS EXPLAINED: 5/7

Outlined triangles (▽) represent companies **developing the product** and **planning to file** with WHO-PQ and/or USFDA




▽ Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

# TRIANGLE CHARTS EXPLAINED: 6/7

Filled triangles (▼) represent companies who have **completed the product development** and have **filed** with WHO-PQ and/or USFDA




▼ Companies filed

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

# TRIANGLE CHARTS EXPLAINED: 7/7

Circled triangles ▼ represent companies who have **completed the product development** and have **received approvals** from WHO-PQ and/or USFDA




▼ **Companies approved**

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

# ADULT HIV

medicinespatentpool.org

# CURRENT SUBLICENSEES

# FOR VIIV-MPP DOLUTEGRAVIR LICENCE

## 13 Dolutegravir Sub-licensee Agreements

adcock ingram

Cipla

DESANO

Emcure cure and beyond

HETERO

LAURUS Labs Chemistry for Better Living

LUPIN

MACLEODS

MANGALAM

MICRO LABS LIMITED

VIATRIS

Strides

SUN PHARMA

*Aurobindo is a direct licensee of ViiV. A tripartite agreement Aurobindo-ViiV-MPP has been signed. For the purposes of this presentation only, data from Aurobindo will be included in the presentation.

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# DTG 50MG: Filing Timelines




***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

## 12 MPP LICENSEES HAVE DEVELOPED DTG 50MG, OF WHICH 11 ARE READY TO COMMERCIALIZE THE PRODUCT

**Licensees Approved*:** Aurobindo, Cipla, Desano, Emcure, Hetero, Laurus, Macleods, Micro Labs, Mylan, Strides, Sun Pharma

1 licensee awaiting WHO-PQ approval

*USFDA and/or WHO-PQ

*Data as of December 2025*

# DTG 50MG: COUNTRY WISE FILING STATUS

## Generic DTG 50mg has been filed in 81 countries, which contribute to an effective coverage of 93.8% PLHIV^

### APPROVED (70)
### 90.5% PLHIV^

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Anguilla*** | **Bhutan** | **Congo** | **Ghana** | **Madagascar** | **Namibia** | **Rwanda** | **Turks and Caicos Islands*** |
| **Antigua and Barbuda*** | **Bolivia** | **Congo, DR** | **Grenada** | **Malawi** | **Nicaragua** | **Saint Lucia*** | **Uganda** |
| **Armenia** | **Botswana** | **Costa Rica*** | **Guatemala** | **Malaysia** | **Niger** | **Saint Vincent and the Grenadines*** | **Ukraine** |
| **Azerbaijan** | **Burkina Faso** | **Côte d'Ivoire** | **India** | **Mauritius** | **Nigeria** | **Senegal** | **Uruguay*** |
| **Bahamas*** | **Burundi** | **Dominica*** | **Indonesia** | **Moldova** | **Oman*** | **South Africa** | **Uzbekistan** |
| Bahrain* | **Cambodia** | **Dominican Republic*** | **Iran*** | **Montserrat*** | **Pakistan** | **Tajikistan** | **Zambia** |
| **Barbados*** | **Cameroon** | **Ecuador** | **Kazakhstan** | **Morocco** | **Panama*** | **Tanzania** | **Zimbabwe** |
| **Belarus** | **Chad** | **Ethiopia** | **Kenya** | **Mozambique** | **Peru*** | **Thailand*** | |
| **Benin** | **Chile*** | **Gabon** | **Kyrgyzstan** | **Myanmar** | **Philippines** | **Turkmenistan** | |

### FILED (11)
### 3.3% PLHIV^

| | | | |
|---|---|---|---|
| **Algeria** | **El Salvador** | **Mali** | **Sri Lanka** |
| **Angola** | **Gambia** | **Paraguay*** | **Viet Nam** |
| Colombia | **Jamaica*** | Saudi Arabia* | |

- New filings and approvals in green *vis-à-vis last update (Q2-25)*
- Countries where DTG 50mg has been sold indicated in **bold type**

* Countries not included in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country

^ People living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG licence agreement and MPP-ViiV DTG UMIC licence) and countries with no patent infringements

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# DTG 50MG IMPACT MAP

## Generic DTG 50mg sales have occurred in 128 countries in which 99.2% of PLHIV^ reside



FILED IN **11** COUNTRIES

APPROVED IN **70** COUNTRIES

SUPPLIED IN **128** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory and countries with no patent infringements
#For licensed territory, refer:
MPP-ViiV DTG adult licence
MPP-ViiV DTG UMIC licence

*Data as of December 2025*

# TDF/3TC/DTG (TLD): Filing Timelines


## 12 MPP LICENSEES HAVE DEVELOPED TDF/3TC/DTG AND ALL ARE READY TO COMMERCIALIZE THE PRODUCT

**Licensees Approved*:** Aurobindo, Cipla, Desano, Emcure, Hetero, Laurus, Lupin, Macleods, Micro Labs, Mylan, Strides, Sun Pharma

1 licensee awaiting USFDA approval

*USFDA and/or WHO-PQ

*Data as of December 2025*

# TDF/3TC/DTG (TLD): COUNTRY WISE FILING STATUS

## TDF/3TC/DTG has been filed in 88 countries which contribute to an effective coverage of 95.5% PLHIV^

### APPROVED (76)
### 91.8% PLHIV^

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Angola | Benin | Congo | Ghana | Kazakhstan | Moldova | Panama* | Suriname* | Uzbekistan |
| Anguilla* | Bhutan | Congo, DR | Grenada* | Kenya | Morocco | Peru* | Tajikistan | Viet Nam |
| Antigua and Barbuda* | Botswana | Côte d'Ivoire | Guatemala | Kyrgyzstan | Montserrat* | Philippines | Tanzania | Zambia |
| Armenia | Burkina Faso | Dominica* | Guyana | Madagascar | Mozambique | Rwanda | Thailand* | Zimbabwe |
| Azerbaijan | Burundi | El Salvador | Haiti | Malawi | Myanmar | Saint Kitts and Nevis* | Turkmenistan | |
| Bahamas* | Cambodia | Eritrea | Honduras | Malaysia | Namibia | Saint Lucia* | Turks and Caicos Islands* | |
| Barbados* | Cameroon | Ethiopia | India | Mali | Nepal | Saint Vincent and the Grenadines* | Uganda | |
| Belarus | Chad | Gabon | Indonesia | Mauritania | Niger | Senegal | Ukraine | |
| Belize* | Chile* | Gambia | Jamaica* | Mauritius | Nigeria | South Africa | Uruguay* | |

### FILED (12)
### 3.7% PLHIV^

| | | |
|---|---|---|
| Bolivia | Ecuador | South Sudan |
| Central African Republic | Guinea | Sri Lanka |
| Colombia | Lebanon | Sudan |
| Costa Rica* | Pakistan | Togo |

New filings and approvals in green *vis-à-vis last update (Q2-25)*
*Countries in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country
^ People living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG licence agreement and MPP-ViiV DTG UMIC licence) and countries with no patent infringements and with compulsory licence issued
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# TLD IMPACT MAP

## Generic TLD sales have occurred in 123 countries in which 99.6% of PLHIV^ reside



FILED IN **12** COUNTRIES

APPROVED IN **76** COUNTRIES

SUPPLIED IN **123** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory and countries with no patent infringements
#For licensed territory, refer:
MPP-ViiV DTG adult licence
MPP-ViiV DTG UMIC licence

*Data as of December 2025*

# COUNTRIES OF SALE OF DTG BASED TREATMENTS (ADULT) (2017 to 2025)

| COUNTRIES OF SALE (129) | | | | | |
|---|---|---|---|---|---|
| Afghanistan | Cabo Verde | Ethiopia | Lao PDR | Nigeria | Suriname |
| Albania | Cambodia | Fiji | Lebanon | **Oman** | Syrian Arab Republic |
| **Algeria** | Cameroon | Gabon | Lesotho | Pakistan | Tajikistan |
| Angola | Central African Republic | Gambia (the) | Liberia | Panama | Tanzania, United Republic of |
| Anguilla | Chad | Georgia | Libya | Papua New Guinea | Thailand |
| Antigua and Barbuda | Chile | Ghana | Madagascar | Paraguay | Timor-Leste |
| Argentina | **Colombia** | Grenada | Malawi | Peru | Togo |
| Armenia | Comoros | Guatemala | Malaysia | Philippines | Tunisia |
| Azerbaijan | Congo | Guinea | Mali | Rwanda | Turkmenistan |
| Bahamas | Congo, DR | Guinea-Bissau | Mauritania | Saint Kitts and Nevis | Turk and Caicos |
| Bangladesh | Costa Rica | Guyana | **Mauritius** | Saint Lucia | Uganda |
| Barbados | Côte d'Ivoire | Haiti | Micronesia | Saint Vincent and the Grenadines | Ukraine |
| Belarus | Cuba | Honduras | Moldova, Republic of | Sao Tome and Principe | Uruguay |
| Belize | Djibouti | India | Mongolia | Senegal | Uzbekistan |
| Benin | Dominica | Indonesia | Montserrat | Seychelles | Venezuela |
| **Bermuda** | Dominican Republic | Iran (Islamic Republic of) | Morocco | Sierra Leone | Vietnam |
| Bhutan | Ecuador | Jamaica | Mozambique | Somalia | Yemen |
| Bolivia | **Egypt** | Jordan | Myanmar | South Africa | Zambia |
| Botswana | El Salvador | Kazakhstan | Namibia | South Sudan | Zimbabwe |
| British Virgin Island | Equatorial Guinea | Kenya | Nepal | Sri Lanka | - |
| Burkina Faso | Eritrea | Kosovo | Nicaragua | State of Palestine | - |
| Burundi | Eswatini | Kyrgyzstan | Niger | Sudan | - |

Analysis includes sales DTG 50mg, TLD, ALD Adult, TAF-ED, TAF-LD, DTG/3TC, DTG/RPV

**Sale of only TLD**

**Sale of only DTG 50mg**

*Data as of December 2025*

# CUMULATIVE PACKS SOLD: DTG 50MG (2017 to 2025)

## ~76 million packs of DTG 50mg sold till December 2025




Note: Packs of 28's, 30's & 90's converted to 30's for this analysis

*Source: confidential sales data by MPP licensees*

*Data as of December 2025*

# CUMULATIVE PACKS SOLD: TLD (2018 to 2025)

## ~1.6 Billion packs of TLD sold till December 2025




Note: Packs of 28's, 84's, 90's & 180's converted to 30's for this analysis

*Source: confidential sales data by MPP licensees*



*Data as of December 2025*

# TOP COUNTRY RECIPIENTS OF ADULT DTG BASED FORMULATIONS (2017 to 2025)

## Top 20 countries receiving Adult DTG based treatments




Analysis includes sales DTG 50mg, TLD, ALD Adult, TAF-ED, TAF-LD, DTG/3TC, DTG/RPV

*Undistributed sales in Sub-Saharan Africa

Note: Packs of 28's, 84's, 90's & 180's converted to 30's for this analysis
Source: confidential sales data by MPP licensees

*Data as of December 2025*

# ABC/3TC/DTG ADULT (ALD): Filing Timelines




## 6 MPP LICENSEES HAVE DEVELOPED ABC/3TC/DTG ADULT FORMULATION, OF WHICH, 5 ARE READY TO COMMERCIALIZE

**Licensees Approved:** Aurobindo, Cipla, Emcure, Hetero, Laurus

1 licensee awaiting USFDA approval | 1 licensee awaiting WHO-PQ approval

*Data as of December 2025*

# ABC/3TC/DTG (ALD): COUNTRY WISE FILING STATUS

**ABC/3TC/DTG has been filed in 41 countries which contribute to an effective coverage of 90.4% PLHIV^**

## APPROVED (28)
## 82.3% PLHIV^

| | | | | | |
|---|---|---|---|---|---|
| Azerbaijan | **Congo DR** | Jamaica* | Mozambique | **South Africa** | **Uzbekistan** |
| Belarus | Ethiopia | **Kazakhstan** | Myanmar | Tanzania | Zambia |
| **Botswana** | **Gabon** | **Kenya** | **Namibia** | **Uganda** | **Zimbabwe** |
| Cambodia | Ghana | **Kyrgyzstan** | Nigeria | **Ukraine** | |
| Cameroon | **India** | Malawi | Rwanda | **Uruguay*** | |

## FILED (13)
## 8.1% PLHIV^

| | | | | |
|---|---|---|---|---|
| **Benin** | Guatemala | Pakistan | **Senegal** | Viet Nam |
| **Côte d'Ivoire** | Indonesia | Philippines | Sri Lanka | |
| El Salvador | Moldova | Saudi Arabia* | Thailand* | |

New filings and approvals in green *vis-à-vis last update (Q2-25)*
Countries where ALD has been sold indicated in **bold type**

- Countries not included in DTG Adult licence but supply by MPP licensees permitted if no patent is being infringed in that country

^ People living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG licence agreement and MPP-ViiV DTG UMIC licence) and countries with no patent infringements

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# ALD ADULT IMPACT MAP

## Generic ALD adult sales have occurred in 33 countries in which 54.7% of PLHIV^ reside



FILED IN **13** COUNTRIES

APPROVED IN **28** COUNTRIES

SUPPLIED IN **33** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory and countries with no patent infringements
#For licensed territory, refer:
MPP-ViiV DTG adult licence
MPP-ViiV DTG UMIC licence

*Data as of December 2025*

# DTG/3TC: Filing Timelines




Companies approved ▼ Companies filed ▽ Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

## 4 MPP LICENSEES HAVE DEVELOPED DTG/3TC FORMULATION, OF WHICH: 3 ARE READY TO COMMERCIALIZE

**Licensee Approved**: Cipla, Emcure, Hetero

1 licensee awaiting USFDA approval | 3 additional licensees developing

*Data as of December 2025*

# DTG/RPV: Filing Timelines


**Companies approved** ▼ Companies filed ▽ Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

**1 MPP LICENSEE HAVE DEVELOPED DTG/RPV FORMULATION AND AWAITS APPROVAL**

*Data as of December 2025*

# CURRENT SUBLICENSEES

# FOR VIIV-MPP DOLUTEGRAVIR LICENCE AND GILEAD-MPP TENOFOVIR ALAFENAMIDE LICENCE

## 7 With both Dolutegravir Tenofovir Alafenamide Sub-licensee Agreements

mpp

adcock ingram

DESANO

Emcure cure and beyond

LAURUS Labs Chemistry for Better Living

LUPIN

MACLEODS

MICRO LABS LIMITED

## 5 Dolutegravir Sub-licensee Agreements

Cipla

HETERO

VIATRIS

Strides

SUN PHARMA

## 1 Tenofovir Alafenamide Sub-licensee Agreements

AUROBINDO

*Aurobindo is a direct licensee of ViiV. A tripartite agreement Aurobindo-ViiV-MPP has been signed. For the purposes of this presentation only, data from Aurobindo will be included in the presentation.

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# TAF/FTC/DTG (TAF-ED): Filing Timelines


## 9 MPP LICENSEES HAVE DEVELOPED TAF/FTC/DTG FORMULATION, OF WHICH: 6 ARE READY TO COMMERCIALIZE

**Licensees Approved:** Aurobindo, Cipla, Hetero, Laurus, Lupin, Viatris

1 licensee awaiting USFDA approval | 4 licensees awaiting WHO-PQ approval | 2 additional licensees developing

*Data as of December 2025*

# TAF/FTC/DTG (TAF-ED): COUNTRY WISE FILING STATUS

**TAF/FTC/DTG has been filed in 54 countries which contribute to an effective coverage of 94.3% of PLHIV^**

| APPROVED (34)<br>87.8% PLHIV^ | | | | |
|---|---|---|---|---|
| Belarus | **Dominican Republic** | Indonesia | **Namibia** | Tanzania |
| **Botswana** | **El Salvador** | Kazakhstan | Niger | **Thailand** |
| Burkina Faso | Ethiopia | **Kenya** | **Nigeria** | **Uganda** |
| **Cambodia** | Gabon | Kyrgyzstan | **Philippines** | **Ukraine** |
| Cameroon | Ghana | Malawi | Rwanda | **Zambia** |
| Congo | **Guatemala** | Mozambique | **South Africa** | **Zimbabwe** |
| Congo, DR | **India** | **Myanmar** | Tajikistan | |

| FILED (20)<br>6.6% PLHIV^ | | | | |
|---|---|---|---|---|
| Angola | Burundi | Guinea | **Mali** | **Senegal** |
| Azerbaijan | Côte d'Ivoire | Jamaica | **Moldova** | **Sri Lanka** |
| Benin | Eritrea | Madagascar | Morocco | Turkmenistan |
| Bolivia | Gambia | Malaysia | Pakistan | Viet Nam |

New filings and approvals in green *vis-à-vis last update (Q4-24)*
Countries where TAF-ED has been sold indicated in **bold type**
^ People living with HIV (2024) in the licensed territory (refer MPP-Gilead TAF licence agreement)
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# TAF-ED IMPACT MAP

## Generic TAF-ED sales have occurred in 30 countries in which 63.3% of PLHIV^ reside



FILED IN **19** COUNTRIES

APPROVED IN **34** COUNTRIES

SUPPLIED IN **30** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory (refer MPP-Gilead TAF licence agreement)

*Data as of December 2025*

# TAF/3TC/DTG (TAF-LD): Filing Timelines




## 4 MPP LICENSEES HAVE DEVELOPED TAF/3TC/DTG FORMULATION, OF WHICH: 4 ARE READY TO COMMERCIALIZE

**Licensees Approved:** Cipla, Laurus, Lupin, Viatris

2 licensees awaiting WHO-PQ approval | 5 additional licensees developing

*Data as of December 2025*

# TAF/3TC/DTG (TAF-LD): COUNTRY WISE FILING STATUS

## TAF/3TC/DTG has been filed in 24 countries

| APPROVED (18) | | | | |
|---|---|---|---|---|
| Botswana | Congo, DR | Malawi | Rwanda | Zambia |
| Burkina Faso | Ethiopia | Mozambique | **South Africa** | **Zimbabwe** |
| Cameroon | India | **Namibia** | **Tanzania** | |
| Congo | **Kenya** | Nigeria | **Uganda** | |

| FILED (6) | | |
|---|---|---|
| Benin | Côte d'Ivoire | Ghana |
| Philippines | **Senegal** | Viet Nam |

New filings and approvals in green *vis-à-vis last update (Q2-25)*
Countries where TAF-LD has been sold indicated in **bold type**
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# TAF-LD IMPACT MAP

## Generic TAF-LD sales have occurred in 14 countries in which 46.1% of PLHIV^ reside



FILED IN **6** COUNTRIES

APPROVED IN **18** COUNTRIES

SUPPLIED IN **14** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
^ People living with HIV (2024) in the licensed territory (refer MPP-Gilead TAF licence agreement)

*Data as of December 2025*

# CURRENT SUBLICENSEES

# FOR GILEAD-MPP TENOFOVIR ALAFENAMIDE LICENCE

## 9 Tenofovir Alafenamide Sub-licensee Agreements

adcock ingram

AUROBINDO

DESANO

Emcure
SUCCESS THROUGH INNOVATION

LAURUS Labs
Chemistry for Better Living

LUPIN

MACLEODS

MICRO LABS LIMITED

NATCO

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# TAF/FTC: Filing Timelines




Companies approved ▼ Companies filed ▽ Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

## 6 MPP LICENSEES HAVE DEVELOPED TAF/FTC FORMULATION, OF WHICH: 4 ARE READY TO COMMERCIALIZE

**Licensees Approved:** Aurobindo, Laurus, Lupin, Macleods

2 licensees awaiting USFDA approval | 1 licensee awaiting WHO PQ approval

*Data as of December 2025*

# BIC/TAF/FTC: REGULATORY AND SUPPLY UPDATE

**1 MPP Licensee (Laurus) has received the tentative approval from USFDA for BIC/TAF/FTC.**

**The product is registered in India & Thailand and supplies have been observed in India as of Dec-25**

*Data as of December 2025*

# PAEDIATRIC HIV

medicinespatentpool.org

# DTG DT PAED (10MG SCORED): Filing Timelines




## 3 MPP LICENSEES HAVE DEVELOPED DTG DT PAED FORMULATION AND ALL ARE READY TO COMMERCIALIZE THE PRODUCT

**Licensees Approved*:** Macleods, Micro labs, Viatris

*USFDA and/or WHO-PQ

*Data as of December 2025*

# DTG DT PAED (10MG SCORED): COUNTRY WISE FILING STATUS

**Generic DTG DT 10mg has been filed in 40 countries which contribute to an effective coverage of 91% of CLHIV^**

| APPROVED (30)<br>86.9% CLHIV^ | | | | | |
|---|---|---|---|---|---|
| **Angola** | **Congo** | **Ghana** | **Malawi** | **Nigeria** | **Togo** |
| **Botswana** | **Congo, DR** | **Guatemala** | **Mali** | **Rwanda** | **Uganda** |
| **Burkina Faso** | **Dominican Republic** | **India** | **Mozambique** | **South Africa** | **Uzbekistan** |
| **Cameroon** | **Ethiopia** | **Kenya** | **Myanmar** | **Tanzania** | **Zambia** |
| **Chad** | **Gambia** | **Madagascar** | **Namibia** | **Thailand** | **Zimbabwe** |

| FILED (10)<br>4.1% CLHIV^ | | |
|---|---|---|
| **Benin** | **Gabon** | **Senegal** |
| **Bolivia** | **Indonesia** | **Viet Nam** |
| **Burundi** | **Niger** | |
| **Côte d'Ivoire** | **Philippines** | |

New filings and approvals in green *vis-à-vis last update (Q2-25)*
Countries where DTG DT 10MG has been sold indicated in **bold type**
^ Children living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG Paed licence agreement) and countries with no patent infringements
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# DTG DT 10MG IMPACT MAP

## Generic pDTG sales have occurred in 105 countries in which 99.6% of CLHIV^ reside



FILED IN **10** COUNTRIES

APPROVED IN **30** COUNTRIES

SUPPLIED IN **105** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ Children living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG Paed licence agreement) and countries with no patent infringements

*Data as of December 2025*

# ABC/3TC/DTG (ALD) PAED: Filing Timelines




## 7 MPP LICENSEES HAVE DEVELOPED ABC/3TC/DTG (ALD) PAED FORMULATION, OF WHICH: 6 ARE READY TO COMMERCIALIZE

**Licensees Approved*:** Aurobindo, Cipla, Lupin, Macleods, Micro Labs, Viatris

2 licensees awaiting USFDA approval | 3 additional licensees developing

*USFDA and/or WHO-PQ

*Data as of December 2025*

# ABC/3TC/DTG PAED: COUNTRY WISE FILING STATUS

**Generic ALD paed has been filed in 31 countries which contribute to an effective coverage of 88.4% of CLHIV^**

| APPROVED (18) 80.7% CLHIV^ | | | | |
|---|---|---|---|---|
| Botswana | **Ethiopia** | **Kenya** | **Rwanda** | **Zimbabwe** |
| **Burkina Faso** | Gabon | **Malawi** | South Africa | |
| **Cameroon** | Gambia | **Mozambique** | **Tanzania** | |
| Chad | **Ghana** | **Myanmar** | **Uganda** | |
| **Congo DR** | India | **Nigeria** | **Zambia** | |

| FILED (13) 7.7% CLHIV^ | | | | |
|---|---|---|---|---|
| **Angola** | **Burundi** | Eritrea | **Namibia** | Ukraine |
| Belarus | Congo | Madagascar | **Niger** | |
| **Benin** | **Côte d'Ivoire** | **Mali** | **Senegal** | |

New filings and approvals in green *vis-à-vis last update (Q2-25)*
Countries where DTG DT 10MG has been sold indicated in **bold type**
^ Children living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG Paed licence agreement) and countries with no patent infringements
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# ALD PAED IMPACT MAP

## Generic pALD sales have occurred in 47 countries in which 76.6% of CLHIV^ reside




**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ Children living with HIV (2024) in the licensed territory (refer MPP-ViiV DTG Paed licence agreement) and countries with no patent infringements

*Data as of December 2025*

# COUNTRIES OF SALE OF DTG BASED TREATMENTS (PAEDIATRIC) 2021 to DECEMBER 2025

| COUNTRIES OF SALE (105) | | | | | |
|---|---|---|---|---|---|
| Albania | Chile | Guatemala | **Malawi** | **Rwanda** | Venezuela |
| **Angola** | **Comoros** | **Guinea** | Malaysia | Sao Tome and Principe | Vietnam |
| Argentina | Congo | **Guinea-Bissau** | **Mali** | **Senegal** | **Yemen** |
| Armenia | **Congo DR** | **Guyana** | **Mauritania** | **Sierra Leone** | **Zambia** |
| Azerbaijan | **Côte d'Ivoire** | **Haiti** | Mauritius | **Somalia** | **Zimbabwe** |
| Bahamas | Cuba | Honduras | Moldova, Republic of | South Africa | - |
| **Bangladesh** | Djibouti | India | Morocco | **South Sudan** | - |
| Belarus | Dominican Republic | Indonesia | **Mozambique** | Sri Lanka | - |
| **Belize** | Ecuador | Iran (Islamic Republic of) | **Myanmar** | Sudan | - |
| **Benin** | Egypt | Jamaica | **Namibia** | Suriname | - |
| **Bhutan** | El Salvador | Jordan | Nepal | Syrian Arab Republic | - |
| Bolivia | Equatorial Guinea | **Kenya** | **Nicaragua** | Tajikistan | - |
| Botswana | Eritrea | Kosovo | **Niger** | **Tanzania, United Republic of** | - |
| **Burkina Faso** | **Eswatini** | Kyrgyzstan | **Nigeria** | **Thailand** | - |
| **Burundi** | **Ethiopia** | **Lao PDR** | Pakistan | Timor-Leste | - |
| Cabo Verde | Fiji | Lebanon | Panama | **Togo** | - |
| **Cambodia** | Gabon | Lesotho | **Papua New Guinea** | Tunisia | - |
| **Cameroon** | Gambia | **Liberia** | Paraguay | **Uganda** | - |
| **Central African Republic** | Georgia | Libya | **Peru** | Ukraine | - |
| Chad | **Ghana** | Madagascar | **Philippines** | Uzbekistan | - |

Analysis includes sales DTG DT 10mg and ALD paed

**Sale of both DTG DT and ALD paed**

Sale of only DTG DT 10mg

*Data as of December 2025*

# TOP COUNTRY RECIPIENTS OF PAEDIATRIC DTG BASED FORMULATIONS (2021 to 2025)

## Top 20 countries receiving Paediatric DTG based treatments




Analysis includes sales of DTG DT 10mg and ALD Paediatric

*Undistributed sales in Sub-Saharan Africa

Note: Packs of 30's and 180's converted to 90's for this analysis
Source: confidential sales data by MPP licensees

*Data as of December 2025*

# TAF/FTC/DTG PAED: FORMULATION DEVELOPMENT TIMELINES

**Two MPP licensees are developing this novel formulation, with tentative SRA filing targeted for 2027**

*Data as of December 2025*

# CURRENT SUBLICENSEES

# FOR VIIV-MPP CABOTEGRAVIR LICENCE

## 3 Cabotegravir-LA Sub-licensee Agreements

AUROBINDO

Cipla

VIATRIS

Note: the following presentation contains updates as of December 2025

# Generic CAB-LA for PrEP: Tentative development timeline




- These timelines are not specific to any generic company; these are averages of the timelines required for different activities as shared by MPP licensees.
- **The earliest possible timeline for filing has shifted from H1 2027 to H2 2027 based on the current estimation by MPP. The main reason for this shift is the dossier batch preparedness.**
- Due to the uncertainty associated with product development, especially for such long-acting products, the timelines quoted here are tentative and can change during development of the product.
- CAB (30mg) is also being developed along with CAB-LA

*Tentative timeline as of Dec 2025*

# VIRAL HEPATITIS

medicinespatentpool.org

# CURRENT SUBLICENSEES

# FOR BMS-MPP DACLATASVIR LICENCE

## 7 Daclatasvir Sub-licensee Agreements

BEXIMCO PHARMA here's to life

Cipla

HETERO

LAURUS Labs Chemistry for Better Living

VIATRIS

NATCO

Zydus Cadila

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# DAC 30MG and 60MG: Filing Timelines




Companies approved

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

## 4 MPP LICENSEES HAVE DEVELOPED DAC 30/60 MG FORMULATION AND ALL ARE READY TO COMMERCIALIZE THE PRODUCT

**Licensees Approved:** Hetero, Laurus, Viatris, Zydus

*Data as of December 2025*

# DAC 30MG AND 60MG: COUNTRY WISE FILING STATUS

**Generic DAC 30/60 mg has been filed in 47 countries which contribute to an effective coverage of 59.5% PLHCV^**

| APPROVED (38)<br>57.1% PLHCV^ | | | | |
|---|---|---|---|---|
| **Azerbaijan** | Ethiopia | **Kyrgyzstan** | **Pakistan** | Uganda |
| **Belarus** | Gabon | Liberia | **Philippines** | **Ukraine** |
| Burkina Faso | Ghana | Malawi | **Rwanda** | **Uzbekistan** |
| **Cambodia** | Guyana | **Malaysia** | Senegal | **Viet Nam** |
| **Cameroon** | **India** | Mozambique | Suriname | Zambia |
| Chad | **Indonesia** | **Myanmar** | **Tanzania** | **Zimbabwe** |
| **Congo** | **Kazakhstan** | Nicaragua | Thailand | |
| Congo, DR | Kenya | **Nigeria** | **Turkmenistan** | |

| FILED (9)<br>2.4% PLHCV^ | | |
|---|---|---|
| **Bolivia** | Mali | **Nepal** |
| Côte d'Ivoire | **Mongolia** | **Paraguay** |
| Haiti | Namibia | Togo |

Countries where either DAC 30mg or DAC 60mg have been sold indicated in **bold type**
^ People living with Hepatitis C (2023) in the licensed territory (refer MPP-BMS DAC licence agreement) and countries with no patent enforcements
# **Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# DAC 60MG IMPACT MAP

## DAC 60MG sales have occurred in 38 countries in which 56.1% of PLHCV^ reside and where MPP licensees have supplied ~1.7 million treatment courses*



FILED IN **9** COUNTRIES

APPROVED IN **38** COUNTRIES

SUPPLIED IN **38** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ People living with Hepatitis C (2025) in the licensed territory (refer MPP-BMS DAC licence agreement) and countries with no patent enforcements

**Note: 1 HCV treatment = 12 weeks therapy (3 packs)*

*Data as of December 2025*

# DAC/SOF: Filing Timelines




## 1 MPP LICENSEE HAS DEVELOPED DAC/SOF FORMULATION AND IS READY TO COMMERCIALIZE THE PRODUCT

**Licensees Approved:** Viatris

*Data as of December 2025*

# DAC/SOF: COUNTRY WISE FILING STATUS

## DAC/SOF has been filed in 20 countries, out of which approval has been received in 17 countries

| APPROVED (17) | | |
|---|---|---|
| **Belarus*** | **Indonesia** | **Tanzania** |
| **Cambodia** | **Kenya** | **Turkmenistan** |
| Côte d'Ivoire | Malawi | **Uganda** |
| **Ethiopia** | **Myanmar** | Zambia |
| Ghana | **Nigeria** | Zimbabwe |
| **India** | **Suriname** | |

Countries where DAC/SOF has been sold indicated in **bold type**
* Countries not included in DAC licence but supply by MPP licensees permitted if no patent is being infringed in that country
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# DAC/SOF IMPACT MAP

## DAC/SOF sales have occurred in 30 countries in which 55.3% of PLHCV^ reside and where MPP licensees have supplied ~271K treatments courses*



FILED IN **3** COUNTRIES

APPROVED IN **17** COUNTRIES

SUPPLIED IN **30** COUNTRIES

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

^ People living with Hepatitis C (2025) in the licensed territory (refer MPP-BMS DAC licence agreement) and countries with no patent enforcements

**Note: 1 HCV treatment = 12 weeks therapy (3 packs)*

*Data as of December 2025*

# CURRENT SUBLICENSEES

# FOR GILEAD-MPP TENOFOVIR ALAFENAMIDE LICENCE

## 9 Tenofovir Alafenamide Sub-licensee Agreements

adcock ingram

AUROBINDO

DESANO

Emcure
SUCCESS THROUGH INNOVATION

LAURUS Labs
Chemistry for Better Living

LUPIN

MACLEODS

MICRO LABS LIMITED

NATCO

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# TAF 25MG: Filing Timelines


Companies approved  Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

## 2 MPP LICENSEES HAVE DEVELOPED TAF 25MG FORMULATION AND BOTH ARE READY TO COMMERCIALIZE THE PRODUCT

**Licensees Approved:** Laurus, Lupin

1 additional licensee awaiting approval

*Data as of December 2025*

# TAF 25MG: COUNTRY WISE FILING STATUS

## Generic TAF 25mg has been filed in 24 countries, of which approval has been received in 16 countries

| APPROVED (16) | | | |
|---|---|---|---|
| **Cambodia** | **Kyrgyzstan** | **Tanzania** | **Ukraine** |
| **India** | **Lao** | **Thailand** | **Uzbekistan** |
| **Indonesia** | **Myanmar** | **Turkmenistan** | **Viet Nam** |
| **Kazakhstan** | **Philippines** | Uganda | Zimbabwe |

| FILED (8) | | |
|---|---|---|
| Azerbaijan | Malawi | Nigeria |
| Ethiopia | Malaysia | Zambia |
| Kenya | Mongolia | |

New filings and approvals in green *vis-à-vis last update (Q2-25)*
Country where TAF 25 mg has been sold indicated in **bold type**
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# COVID-19

medicinespatentpool.org

# CURRENT SUB-LICENSEES

# FOR MSD-MPP MOLNUPIRAVIR LICENCE

## 4 Molnupiravir Sub-licensee Agreements

DESANO

FOSUN PHARMA

kimia farma

MSN
Research for Better Medicines

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# MOL 200MG: Filing Timelines




**Companies approved** ▼ Companies filed ▽ Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

## 3 MPP LICENSEES HAVE DEVELOPED MOL 200MG FORMULATION, OF WHICH: 2 ARE READY TO COMMERCIALIZE

**Licensees Approved:** Desano, Fosun

1 licensee awaiting WHO-PQ approval | 1 additional licensee developing

*Data as of December 2025*

# CURRENT SUB-LICENSEES

# FOR PFIZER-MPP NIRMATRELVIR LICENCE

## 12 Nirmatrelvir Sub-licensee Agreements

APELOA 普洛

Arene Lifesciences Limited

CELLTRION

Cipla

DESANO

DONGBANG FTL
DongBang Future Tech & Life Co., Ltd.

FOSUN PHARMA

HETERO

VIATRIS

NEOLPHARMA

华海药业
HUAHAI PHARMACEUTICAL

JIUZHOU
Pharmaceutical

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# NIR + RTV (Co-pack) : Filing Timelines




## 9 MPP LICENSEES HAVE DEVELOPED NIR+RTV (CO-PACK) FORMULATION, OF WHICH: 7 ARE READY TO COMMERCIALIZE

**Licensees Approved:** Apeloa, Celltrion, Desano, Fosun, Hetero, Huahai, Viatris

2 licensees awaiting WHO-PQ approval

*Data as of December 2025*

# COVID-19 PRODUCTS: COUNTRY WISE FILING STATUS

## NIR300mg +RTV100mg (Co-pack) has been filed in 24 countries, of which approval has been received in 10 countries

| APPROVED (10) | | |
|---|---|---|
| Botswana | **Ghana** | South Africa |
| **Cambodia** | India | Tanzania |
| Congo DR | **Malawi** | |
| **Ethiopia** | Mali | |

| FILED (14) | | | |
|---|---|---|---|
| Burkina Faso | Kenya | Nicaragua | Viet Nam |
| El Salvador | Mongolia | Philippines | Zimbabwe |
| Gabon | Morocco | **Senegal** | |
| Honduras | Namibia | Uganda | |

## MOL 200mg has been approved in 2 countries

| APPROVED (2) | |
|---|---|
| **India** | **Indonesia** |

Country where Covid-19 products have been sold indicated in **bold type**
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# CANCER

medicinespatentpool.org

# CURRENT SUBLICENSEES

# FOR NOVARTIS-MPP NILOTINIB LICENCE

## 4 Nilotinib Sub-licensee Agreements

BrightGene 博瑞医药

Dr.Reddy's

eugia

HETERO

Note: the following presentation contains updates as of December 2025, however approvals through March 2026 are included.

# NTB 150MG/200MG : Filing Timelines




**Companies approved** ▼ Companies filed ▽ Companies planning to file

***Note:*** *Each triangle represents a manufacturer and timelines represent date of filing*

## 3 MPP LICENSEES HAVE DEVELOPED NTB 150MG/200MG FORMULATION, OF WHICH: 2 ARE READY TO COMMERCIALIZE

**Licensees Approved:** Dr. Reddy's*, Hetero

1 licensee awaiting SRA approval | 1 additional licensee developing

* has approval for 50mg strength also

*Data as of December 2025*

# NTB 150MG AND 200MG: COUNTRY WISE FILING STATUS

## NTB 150mg/200mg has been filed in 26 countries, of which approval has been received in 12 countries

### APPROVED (12)

| | | |
|---|---|---|
| Azerbaijan | Guatemala | Nicaragua |
| Costa Rica | Honduras* | Paraguay |
| Dominican Republic | **Indonesia** | **Philippines** |
| **El Salvador** | Myanmar | Sri Lanka** |

### FILED (14)

| | | | |
|---|---|---|---|
| Botswana | Kenya | Tajikistan | Zambia |
| Cambodia | Morocco | Tanzania | Zimbabwe |
| Ethiopia | Namibia | Uganda | |
| Ghana | Nepal | Ukraine | |

- Approval only for 200mg, ** approval only for 150mg

New filings and approvals in green *vis-à-vis last update (Q2-25)*
Country where NTB 150/200mg has been sold indicated in **bold type**
**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

*Data as of December 2025*

# Thank you

Unitaid
SAVE LIVES FASTER

Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra
Swiss Agency for Development and Cooperation SDC

MINISTÈRE DE L'EUROPE ET DES AFFAIRES ÉTRANGÈRES
Liberté
Égalité
Fraternité

From the People of Japan

In partnership with Canada

german cooperation
DEUTSCHE ZUSAMMENARBEIT

Government of Flanders

Coefficient Giving